You are on Trendlyne United States. Click here to go to India website or make United States as your default
person reading

About Cardiff Oncology Inc - Company Information, Overview, History and Profile

What does Cardiff Oncology Inc do?

Cardiff Oncology Inc is a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the greatest unmet medical need. It is focusing on clinical programs in indications such as RAS-mutated metastatic colorectal cancer ("mCRC"), as well as in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma ("mPDAC"), small cell lung cancer ("SCLC"), and triple negative breast cancer ("TNBC"). Geographically, the company only operates in the United States.

Cardiff Oncology Inc Management structure

All Gross Remunerations are in USD
Mr. James E. Levine
Chief Financial Officer and Principal Accounting Officer
-
2024
Gross Remuneration
Year
Dr. Mark Erlander, PhD
Director and Chief Executive Officer
-
2024
Gross Remuneration
Year

Cardiff Oncology Inc Board of directors

All Gross Remunerations are in USD
Dr. Gary W. Pace,PhD
Independent Director
-
2024
Gross Remuneration
Year
Dr. James O. Armitage,M.D.
Independent Director
-
2024
Gross Remuneration
Year
Dr. Rodney S. Markin,M.D.,PhD
Chairman of the Board
-
2024
Gross Remuneration
Year
Dr. Renee P. Tannenbaum, D.Pharm.
Independent Director
-
2024
Gross Remuneration
Year
Dr. Mark Erlander, PhD
Director and Chief Executive Officer
-
2024
Gross Remuneration
Year
Ms. Lale White
Independent Director
-
2024
Gross Remuneration
Year